Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer
作者： M. Karthaus , Harald Ballo , Wolgang Abenhardt , Tilmann Steinmetz , Thomas Geer
DOI: 10.1159/000086971
关键词:
摘要: Background: Unpredictable and severe diarrhea (NCI grade ≧3) remains a life-threatening adverse event in patients treated with irinotecan (CPT-11). The aim of this study was to eval
karger.com
sci-hub.se 参考文章(26)
Koichiro Kudo, Yuichiro Takeda, Shouji Kudoh, Yoshiko Akiyama, Satoko Handa, Kunihiko Kobayashi, Tomoyuki Soma, [A case-control study of prevention of irinotecan-induced diarrhea: the reducing side effects of irinotecan by oral alkalization combined with control of defecation]. Gan to kagaku ryoho. Cancer & chemotherapy. ,vol. 29, pp. 1171- 1177 ,(2002)
J F Seitz, M Ychou, J Duffour, O Boutet, D Castera, A Kramar, P Senesse, S Gourgou, Efficacy of prophylactic anti-diarrhoeal treatment in patients receiving Campto for advanced colorectal cancer. Anticancer Research. ,vol. 22, pp. 3727- 3731 ,(2002)
Barbara Pro, Richard Lozano, Jaffer A. Ajani, Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea. Investigational New Drugs. ,vol. 19, pp. 341- 343 ,(2001) , 10.1023/A:1010678214152
Susan Ceryak, Linan Ha, Patricia Latham, Yasushi Matsuzaki, Bernard Bouscarel, Kazuhiko Arimori, Kunihiko Kobayashi, Tadashi Ikegami, Intestinal Alkalization As a Possible Preventive Mechanism in Irinotecan (CPT-11)-induced Diarrhea Cancer Research. ,vol. 62, pp. 179- 187 ,(2002)
P Rougier, R Bugat, J Y Douillard, S Culine, E Suc, P Brunet, Y Becouarn, M Ychou, M Marty, J M Extra, J Bonneterre, A Adenis, J F Seitz, G Ganem, M Namer, T Conroy, S Negrier, Y Merrouche, F Burki, M Mousseau, P Herait, M Mahjoubi, Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. Journal of Clinical Oncology. ,vol. 15, pp. 251- 260 ,(1997) , 10.1200/JCO.1997.15.1.251
M L Rothenberg, J R Eckardt, J G Kuhn, H A Burris, J Nelson, S G Hilsenbeck, G I Rodriguez, A M Thurman, L S Smith, S G Eckhardt, G R Weiss, G L Elfring, D A Rinaldi, L J Schaaf, D D Von Hoff, Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. Journal of Clinical Oncology. ,vol. 14, pp. 1128- 1135 ,(1996) , 10.1200/JCO.1996.14.4.1128
F Saliba, R Hagipantelli, J L Misset, G Bastian, G Vassal, M Bonnay, P Herait, C Cote, M Mahjoubi, D Mignard, E Cvitkovic, Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. Journal of Clinical Oncology. ,vol. 16, pp. 2745- 2751 ,(1998) , 10.1200/JCO.1998.16.8.2745
J. Zidan, N. Haim, A. Beny, M. Stein, E. Gez, A. Kuten, Octreotide in the treatment of severe chemotherapy-induced diarrhea Annals of Oncology. ,vol. 12, pp. 227- 229 ,(2001) , 10.1023/A:1008372228462
Yoshio Kase, Terumasa Hayakawa, Yuji Togashi, Tetsuya Kamataki, Relevance of Irinotecan Hydrochloride-Induced Diarrhea to the Level of Prostaglandin E2 and Water Absorption of Large Intestine in Rats Japanese Journal of Pharmacology. ,vol. 75, pp. 399- 405 ,(1997) , 10.1254/JJP.75.399
Vittorio Gebbia, Ignazio Carreca, Antonio Testa, Roberto Valenza, Giuseppina Curto, Giuseppe Cannata, Nicola Borsellino, Mario Adelfio Latteri, Calogero Cipolla, Matteo Florena, Nicola Gebbia, Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy Anti-Cancer Drugs. ,vol. 4, pp. 443- 445 ,(1993) , 10.1097/00001813-199308000-00004